SAGE-718 ( DrugBank: Sage )
2 diseases
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
6 | パーキンソン病 | 2 |
8 | ハンチントン病 | 4 |
6. パーキンソン病
臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05318937 (ClinicalTrials.gov) | July 6, 2022 | 1/4/2022 | A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment | A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Parkinson's Disease Cognitive Impairment | Parkinson Disease;Cognitive Dysfunction | Drug: SAGE-718;Drug: SAGE-718-matching placebo | Sage Therapeutics | NULL | Recruiting | 50 Years | 75 Years | All | 76 | Phase 2 | United States |
2 | NCT04476017 (ClinicalTrials.gov) | September 11, 2020 | 15/7/2020 | A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI) | An Open-Label Evaluation of the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment | Parkinson Disease;Cognitive Dysfunction | Drug: SAGE-718 | Sage Therapeutics | NULL | Completed | 50 Years | 75 Years | All | 18 | Phase 2 | United States |
8. ハンチントン病
臨床試験数 : 242 / 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05655520 (ClinicalTrials.gov) | December 14, 2022 | 9/12/2022 | A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease | A Phase 3, Multicenter, Open-label Safety Study to Evaluate the Long-term Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease | Huntington Disease | Drug: SAGE-718 | Sage Therapeutics | NULL | Recruiting | 25 Years | 65 Years | All | 300 | Phase 3 | United States |
2 | NCT05358821 (ClinicalTrials.gov) | June 22, 2022 | 27/4/2022 | A Study to Evaluate the Effect of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease | A 28-Day Randomized, Placebo-Controlled, Double-Blind, Parallel Groups and Normative Comparison Study to Evaluate the Effect of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease | Huntington Disease | Drug: SAGE-718;Drug: Placebo | Sage Therapeutics | NULL | Recruiting | 25 Years | 65 Years | All | 80 | Phase 2 | United States |
3 | NCT05107128 (ClinicalTrials.gov) | February 10, 2022 | 25/10/2021 | A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD) | A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease | Huntington's Disease | Drug: SAGE-718;Drug: Placebo | Sage Therapeutics | NULL | Recruiting | 25 Years | 65 Years | All | 178 | Phase 2 | United States;Australia;Canada;United Kingdom |
4 | NCT03787758 (ClinicalTrials.gov) | February 28, 2019 | 17/12/2018 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B | A Phase 1, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Healthy Adults With an Open-label Cohort of Patients With Huntington's Disease | Huntington Disease | Drug: SAGE-718 | Sage Therapeutics | NULL | Completed | 18 Years | 70 Years | All | 6 | Phase 1 | United States |